Vulpinic acid

Vulpinic acid, a lichen metabolite, decreases H2O2-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC) . Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research[1][2].

Product Specifications

CAS Number

[521-52-8]

UNSPSC

12352005

Hazard Statement

H302

Target

Bacterial; Endogenous Metabolite; Reactive Oxygen Species (ROS)

Type

Natural Products

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vulpinic-acid.html

Purity

99.62

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC(/C(C1=CC=CC=C1)=C2C(O)=C(C3=CC=CC=C3)C(O\2)=O)=O

Molecular Formula

C19H14O5

Molecular Weight

322.31

Precautions

P264-P270-P330-P501

References & Citations

[1]E Sahin, et al. Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress-related diseases, such as atherosclerosis. Hum Exp Toxicol. 2019 Jun;38 (6) :675-684.|[2]M Lauterwein, et al. In vitro activities of the lichen secondary metabolites vulpinic acid, (+) -usnic acid, and (-) -usnic acid against aerobic and anaerobic microorganisms. Antimicrob Agents Chemother. 1995 Nov;39 (11) :2541-3.